Sorry, you need to enable JavaScript to visit this website.

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated
Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation. An Open-Label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-Stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Category & Conditions: Cancer
Medicine: MEKTOVI® TABLETS(BINIMETINIB) OPDIVO®(NIVOLUMAB) YERVOY®(IPILIMUMAB)
ClinicalTrials.gov Identifier (NCT): NCT03271047
Protocol ID: C4211004
    Share
PrintDownload
Open Plain Language Summary Result: Click here